Sarepta Therapeutics downgraded by Cantor Fitzgerald
$SRPT
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald downgraded Sarepta Therapeutics from Overweight to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2025 | $24.00 | Buy → Hold | TD Cowen |
| 6/17/2025 | Peer Perform | Wolfe Research | |
| 6/16/2025 | Overweight → Equal-Weight | Morgan Stanley | |
| 6/16/2025 | Overweight → Neutral | Cantor Fitzgerald | |
| 6/16/2025 | Buy → Neutral | BofA Securities | |
| 6/16/2025 | $70.00 | Outperform → Market Perform | BMO Capital Markets |
| 6/16/2025 | $36.00 | Overweight → Neutral | Piper Sandler |
| 6/16/2025 | $10.00 | Neutral → Sell | H.C. Wainwright |
8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)
10-Q - Sarepta Therapeutics, Inc. (0000873303) (Filer)
DEFA14A - Sarepta Therapeutics, Inc. (0000873303) (Filer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)